Browsing Tag
iNGENū CRO
1 post
Zelira Therapeutics (ASX:ZLD) secures $33m to advance HOPE 1 autism therapy through U.S. FDA trials
Find out how Zelira’s US$33M SPV deal with ThirdGate Capital is reshaping its FDA strategy for HOPE 1 and shaking up the autism biotech space.